Annovis Bio Inc. Advances in Alzheimer’s and Parkinson’s Disease Treatment: Key FAQs

What is Annovis Bio Inc. working on?

Annovis Bio Inc. is developing innovative therapies, including its lead drug candidate buntanetap, aimed at treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s by targeting multiple neurotoxic proteins to restore brain function.

What progress has Annovis Bio made in its clinical trials?

Following a successful Phase 2 meeting with the FDA, Annovis Bio has received clearance to initiate two Phase 3 studies for Alzheimer’s disease, focusing on symptomatic relief and disease-modifying potential, with the first study starting in Q1 2025.

How has Annovis Bio secured funding for its Phase 3 trials?

Annovis Bio raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, ensuring financial stability to proceed with its Phase 3 clinical trials.

What are the new developments in Annovis Bio’s intellectual property?

Annovis Bio has strengthened its intellectual property portfolio with new patents for buntanetap combination therapies, enhancing its position in developing treatments for neurodegenerative diseases.

Who has Annovis Bio recently appointed to support its clinical trials?

Annovis Bio has expanded its team with the appointment of Senior Clinical Scientist Dr. Matthew Peterson to support the quality and completion of its clinical trials.

Where can I find more information about Annovis Bio Inc.?

For more information, visit Annovis Bio’s website at www.AnnovisBio.com, and their social channels on LinkedIn, X, and YouTube. The latest news and updates are also available in the company’s newsroom at https://ibn.fm/ANVS.

Why is Annovis Bio’s progress significant?

Annovis Bio’s progress is significant because it represents a critical advancement in the treatment of Alzheimer’s and Parkinson’s diseases, offering potential new therapies that could improve the quality of life for patients suffering from these neurodegenerative conditions.

When are the Phase 3 trials for Alzheimer’s disease expected to start?

The first Phase 3 trial for Alzheimer’s disease, evaluating symptomatic relief, is slated to start in Q1 2025, with an 18-month trial to assess disease-modifying potential following thereafter.